Medical - Distribution
Compare Stocks
5 / 10Stock Comparison
OMI vs MMSI vs HSIC vs ATRC vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Distribution
Medical - Instruments & Supplies
Medical - Devices
OMI vs MMSI vs HSIC vs ATRC vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Distribution | Medical - Instruments & Supplies | Medical - Distribution | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $171M | $3.72B | $8.09B | $1.41B | $112.69B |
| Revenue (TTM) | $2.76B | $1.54B | $13.18B | $552M | $25.12B |
| Net Income (TTM) | $-1.10B | $139M | $398M | $-5M | $3.25B |
| Gross Margin | — | 48.7% | 29.1% | 75.5% | 63.5% |
| Operating Margin | 1.0% | 12.2% | 5.8% | -0.4% | 22.4% |
| Forward P/E | 2.3x | 15.5x | 13.3x | 370.7x | 19.6x |
| Total Debt | $320M | $898M | $3.69B | $88M | $14.86B |
| Cash & Equiv. | $282M | $449M | $156M | $167M | $4.01B |
OMI vs MMSI vs HSIC vs ATRC vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Feb 26 | Return |
|---|---|---|---|
| Owens & Minor, Inc. (OMI) | 100 | 28.2 | -71.8% |
| Merit Medical Syste… (MMSI) | 100 | 180.2 | +80.2% |
| Henry Schein, Inc. (HSIC) | 100 | 124.3 | +24.3% |
| AtriCure, Inc. (ATRC) | 100 | 77.2 | -22.8% |
| Stryker Corporation (SYK) | 100 | 188.8 | +88.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OMI vs MMSI vs HSIC vs ATRC vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OMI is the #2 pick in this set and the best alternative if value is your priority.
- Lower P/E (2.3x vs 370.7x)
MMSI is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 214.6% 10Y total return vs SYK's 187.1%
- Lower volatility, beta 0.71, Low D/E 56.7%, current ratio 4.34x
- Beta 0.71, current ratio 4.34x
HSIC ranks third and is worth considering specifically for momentum.
- +5.9% vs OMI's -71.1%
ATRC is the clearest fit if your priority is growth exposure.
- Rev growth 14.9%, EPS growth 74.7%, 3Y rev CAGR 17.4%
- 14.9% revenue growth vs OMI's -74.2%
SYK carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- PEG 1.32 vs HSIC's 4.21
- 12.9% margin vs OMI's -39.8%
- Beta 0.55 vs OMI's 1.44
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.9% revenue growth vs OMI's -74.2% | |
| Value | Lower P/E (2.3x vs 370.7x) | |
| Quality / Margins | 12.9% margin vs OMI's -39.8% | |
| Stability / Safety | Beta 0.55 vs OMI's 1.44 | |
| Dividends | 1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +5.9% vs OMI's -71.1% | |
| Efficiency (ROA) | 6.9% ROA vs OMI's -44.9%, ROIC 11.4% vs 1.8% |
OMI vs MMSI vs HSIC vs ATRC vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
OMI vs MMSI vs HSIC vs ATRC vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SYK leads in 3 of 6 categories
OMI leads 1 • MMSI leads 0 • HSIC leads 0 • ATRC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — ATRC and SYK each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 45.5x ATRC's $552M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to OMI's -39.8%. On growth, ATRC holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.8B | $1.5B | $13.2B | $552M | $25.1B |
| EBITDAEarnings before interest/tax | $277M | $290M | $1.1B | $13M | $6.3B |
| Net IncomeAfter-tax profit | -$1.1B | $139M | $398M | -$5M | $3.2B |
| Free Cash FlowCash after capex | -$353M | $274M | $561M | $54M | $4.3B |
| Gross MarginGross profit ÷ Revenue | — | +48.7% | +29.1% | +75.5% | +63.5% |
| Operating MarginEBIT ÷ Revenue | +1.0% | +12.2% | +5.8% | -0.4% | +22.4% |
| Net MarginNet income ÷ Revenue | -39.8% | +9.0% | +3.0% | -0.8% | +12.9% |
| FCF MarginFCF ÷ Revenue | -12.8% | +17.8% | +4.3% | +9.7% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -146.3% | +7.8% | +7.7% | +14.3% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +4.5% | +38.8% | +14.9% | +101.6% | +56.0% |
Valuation Metrics
OMI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 38% valuation discount to SYK's 35.0x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $171M | $3.7B | $8.1B | $1.4B | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $209M | $4.2B | $11.6B | $1.3B | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.16x | 29.26x | 21.56x | -115.83x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | 2.31x | 15.46x | 13.26x | 370.67x | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 6.84x | — | 2.36x |
| EV / EBITDAEnterprise value multiple | 1.70x | 13.06x | 10.87x | 77.75x | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 0.06x | 2.45x | 0.61x | 2.63x | 4.49x |
| Price / BookPrice ÷ Book value/share | — | 2.38x | 1.79x | 2.70x | 5.02x |
| Price / FCFMarket cap ÷ FCF | — | 17.24x | 14.12x | 29.15x | 26.31x |
Profitability & Efficiency
SYK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-21 for OMI. ATRC carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to HSIC's 0.77x. On the Piotroski fundamental quality scale (0–9), MMSI scores 6/9 vs OMI's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.1% | +8.9% | +8.2% | -1.0% | +15.0% |
| ROA (TTM)Return on assets | -44.9% | +5.2% | +3.6% | -0.7% | +6.9% |
| ROICReturn on invested capital | +1.8% | +7.2% | +7.1% | -0.6% | +11.4% |
| ROCEReturn on capital employed | +1.3% | +7.9% | +9.8% | -0.6% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.57x | 0.77x | 0.18x | 0.66x |
| Net DebtTotal debt minus cash | $38M | $450M | $3.5B | -$79M | $10.8B |
| Cash & Equiv.Liquid assets | $282M | $449M | $156M | $167M | $4.0B |
| Total DebtShort + long-term debt | $320M | $898M | $3.7B | $88M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -0.12x | 10.74x | 4.59x | 0.47x | 6.72x |
Total Returns (Dividends Reinvested)
SYK leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $655 for OMI. Over the past 12 months, HSIC leads with a +5.9% total return vs OMI's -71.1%. The 3-year compound annual growth rate (CAGR) favors SYK at 1.8% vs OMI's -49.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -3.4% | -27.9% | -8.2% | -29.2% | -15.2% |
| 1-Year ReturnPast 12 months | -71.1% | -33.8% | +5.9% | -8.3% | -22.5% |
| 3-Year ReturnCumulative with dividends | -87.4% | -26.5% | -11.7% | -41.8% | +5.5% |
| 5-Year ReturnCumulative with dividends | -93.5% | -3.6% | -12.5% | -64.2% | +21.5% |
| 10-Year ReturnCumulative with dividends | -86.2% | +214.6% | +5.3% | +95.1% | +187.1% |
| CAGR (3Y)Annualised 3-year return | -49.9% | -9.8% | -4.0% | -16.5% | +1.8% |
Risk & Volatility
Evenly matched — HSIC and SYK each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than OMI's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HSIC currently trades 79.0% from its 52-week high vs OMI's 23.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 0.71x | 0.73x | 1.03x | 0.55x |
| 52-Week HighHighest price in past year | $9.55 | $100.19 | $89.29 | $43.18 | $404.87 |
| 52-Week LowLowest price in past year | $1.84 | $59.74 | $61.95 | $26.62 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +23.5% | +62.2% | +79.0% | +64.4% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 46.5 | 34.9 | 39.1 | 45.0 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 690K | 769K | 1.2M | 669K | 2.1M |
Analyst Outlook
SYK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: OMI as "Hold", MMSI as "Buy", HSIC as "Hold", ATRC as "Buy", SYK as "Buy". Consensus price targets imply 82.3% upside for ATRC (target: $51) vs 22.6% for HSIC (target: $86). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $95.00 | $86.43 | $50.67 | $403.69 |
| # AnalystsCovering analysts | 10 | 13 | 32 | 19 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | 0 | — | 1 | — | 34 |
| Dividend / ShareAnnual DPS | — | — | — | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +10.5% | +0.8% | 0.0% |
SYK leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). OMI leads in 1 (Valuation Metrics). 2 tied.
OMI vs MMSI vs HSIC vs ATRC vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OMI or MMSI or HSIC or ATRC or SYK a better buy right now?
For growth investors, AtriCure, Inc.
(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -74. 2% for Owens & Minor, Inc. (OMI). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Merit Medical Systems, Inc. (MMSI) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OMI or MMSI or HSIC or ATRC or SYK?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus Stryker Corporation at 35. 0x. On forward P/E, Owens & Minor, Inc. is actually cheaper at 2. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Henry Schein, Inc. 's 4. 21x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — OMI or MMSI or HSIC or ATRC or SYK?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.
5%, compared to -93. 5% for Owens & Minor, Inc. (OMI). Over 10 years, the gap is even starker: MMSI returned +214. 6% versus OMI's -86. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OMI or MMSI or HSIC or ATRC or SYK?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
55β versus Owens & Minor, Inc. 's 1. 44β — meaning OMI is approximately 164% more volatile than SYK relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 77% for Henry Schein, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — OMI or MMSI or HSIC or ATRC or SYK?
By revenue growth (latest reported year), AtriCure, Inc.
(ATRC) is pulling ahead at 14. 9% versus -74. 2% for Owens & Minor, Inc. (OMI). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -201. 1% for Owens & Minor, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OMI or MMSI or HSIC or ATRC or SYK?
Stryker Corporation (SYK) is the more profitable company, earning 12.
9% net margin versus -39. 8% for Owens & Minor, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -0. 6% for ATRC. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OMI or MMSI or HSIC or ATRC or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Owens & Minor, Inc. (OMI) trades at 2. 3x forward P/E versus 370. 7x for AtriCure, Inc. — 368. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 82. 3% to $50. 67.
08Which pays a better dividend — OMI or MMSI or HSIC or ATRC or SYK?
In this comparison, SYK (1.
1% yield) pays a dividend. OMI, MMSI, HSIC, ATRC do not pay a meaningful dividend and should not be held primarily for income.
09Is OMI or MMSI or HSIC or ATRC or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, OMI: -86. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OMI and MMSI and HSIC and ATRC and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
SYK pays a dividend while OMI, MMSI, HSIC, ATRC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.